← Leaderboards
Charles C-Y Shih
Androscience Corporation
$1,963,555
Attributed
$1,963,555
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $862.2K · FY2006–14$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$1,963,555 · 5
By mechanism
U01$862,197 · 1
R44$801,607 · 1
R43$200,001 · 2
R41$99,750 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Androgen Receptor”
- Susan E. Hankinson · University Of Massachusetts Amherst$24,278,267
- Diane E Merry · Thomas Jefferson University$17,810,180
- Charles L Sawyers · Sloan-Kettering Inst Can Research$17,232,913
- Richard D Schulick · Johns Hopkins University$17,086,121
- Shalendar Bhasin · La Biomed Res Inst/ Harbor Ucla Med Ctr$16,194,198
- Xiaoqi Liu · Harvard University$15,300,481
Research focus
Androgen ReceptorMedicalPharmaceutical PreparationsBiological AvailabilityPlayClinical TrialsPreclinical StudyPre-ClinicalToxicologyAndrogen InhibitorSafetySymptomsClinical ResearchAffectAndrogensExhibitsAbateEffective TherapyFaceAndrogen AntagonistsDrug FormulationsAdme StudyAnalogDrug Candidate
Grant awards (8)
Development of an Oral Therapeutic Drug for Spinal and Bulbar Muscular Atrophy$1
U01 · FY2014 · NS · contact PI
Development of an Oral Therapeutic Drug for Spinal and Bulbar Muscular Atrophy$1
U01 · FY2013 · NS · contact PI
Development of an Oral Therapeutic Drug for Spinal and Bulbar Muscular Atrophy$862,195
U01 · FY2011 · NS · contact PI
A New Topical Antiandrogen Benefits Acne Treatment$355,580
R44 · FY2007 · AR · contact PI
A New Topical Antiandrogen Benefits Acne Treatment$446,027
R44 · FY2006 · AR · contact PI
A New Topical Antiandrogen Benefits Acne Treatment$100,001
R43 · FY2004 · AR
Cell-Based High Throughput Screening for Anti-Androgens$100,000
R43 · FY2002 · CA
Anti-androgenic mechanism of a new compound$99,750
R41 · FY2002 · CA